1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2020, provides an overview of the Women Infertility (Women's Health) pipeline landscape.
Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 21, 16, 1, 2, 22, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.
Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionWomen Infertility - Overview
Women Infertility - Therapeutics Development
Women Infertility - Therapeutics Assessment
Women Infertility - Companies Involved in Therapeutics Development
Women Infertility - Drug Profiles
Women Infertility - Dormant Projects
Women Infertility - Discontinued Products
Women Infertility - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Women Infertility, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Women Infertility - Pipeline by Adynxx Inc, H2 2020
- Women Infertility - Pipeline by AlphaMab Co Ltd, H2 2020
- Women Infertility - Pipeline by Amega Biotech, H2 2020
- Women Infertility - Pipeline by Anelleo Inc, H2 2020
- Women Infertility - Pipeline by Aprilbio Co Ltd, H2 2020
- Women Infertility - Pipeline by Aptorum Group Ltd, H2 2020
- Women Infertility - Pipeline by ARTham Therapeutics Inc, H2 2020
- Women Infertility - Dormant Projects, H2 2020
- Women Infertility - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Women Infertility, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adynxx Inc
- AlphaMab Co Ltd
- Amega Biotech
- Anelleo Inc
- Aprilbio Co Ltd
- Aptorum Group Ltd
- ARTham Therapeutics Inc
- ASKA Pharmaceutical Co Ltd
- Auritec Pharmaceuticals Inc
- Bayer AG
- Beijing Fogangren Bio-Pharm Tech Co Ltd
- Beijing SL Pharmaceutical Co Ltd
- Bharat Serums And Vaccines Ltd
- Bol Pharma
- Bopin (Shanghai) Biomedical Technology Co Ltd
- Chugai Pharmaceutical Co Ltd
- Context Therapeutics LLC
- Daewoong Pharmaceutical Co Ltd
- ElexoPharm GmbH
- Enteris BioPharma Inc
- Eurofarma Laboratorios SA
- Evestra Inc
- Evotec SE
- FemmePharma Global Healthcare Inc
- Ferring International Center SA
- Ferring Pharmaceuticals Inc
- Forendo Pharma Ltd
- GeneScience Pharmaceuticals Co Ltd
- Genome & Co
- Glycotope GmbH
- Igenomix SL
- Igyxos SA
- Immunitor Inc
- Isifer AB
- Jiangsu Hengrui Medicine Co Ltd
- Kissei Pharmaceutical Co Ltd
- LG Chem Ltd
- Livzon Pharmaceutical Group Co Ltd
- Luye Pharma Group Ltd
- Mitsubishi Tanabe Pharma Corp
- Myovant Sciences Ltd
- Navad Life Sciences Pte Ltd
- Nippon Shinyaku Co Ltd
- NutriBand Inc
- ObsEva SA
- Oxolife SL
- Pangen Biotech Inc
- Park Active Molecules
- Philogen SpA
- Predictive Therapeutics LLC
- PregLem SA
- Reven Pharmaceuticals Inc
- Richter Gedeon Nyrt
- Shanghai Jing Ze Biotechnology Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Suzhou JiSheng Pharmaceutical Co Ltd
- SYNG Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Temple Therapeutics BV
- TiumBio Co Ltd
- Trophogen Inc
- ValiRx Plc
- Viramal Ltd
- Xbrane Biopharma AB
